OriBiotech is a rising innovator in the field of cell and gene therapy manufacturing, poised to transform the accessibility and scalability of these life-saving therapies. As the company moved into a critical growth stage, preparing to launch its first product, IRO, Ori recognized the importance of refining its brand and messaging to match the groundbreaking potential of its technology.

KARV partnered with OriBiotech to develop strategic brand positioning for both the company and IRO, a product designed to address one of the greatest challenges in the industry: the scalability of highly manual manufacturing processes. Cell and gene therapies, which offer curative treatments for devastating diseases, often face production bottlenecks due to labor-intensive workflows. IRO redefines this landscape, automating and scaling critical processes to lower costs, improve consistency, and make these therapies accessible to more patients than ever before.

Our collaboration included reimagining Ori’s corporate tagline, "Manufacturing Brighter Futures," to align with their vision of scaling hope and transforming lives. We crafted a cohesive narrative and creative framework that positioned IRO as an industry game-changer. These efforts culminated in a new website, developed with a UK-based programming partner, which served as a dynamic platform to showcase Ori’s innovation and amplify IRO’s market launch.

To mark this milestone, KARV captured the energy and excitement of IRO’s first in-person product launch through emotive video and photography, telling the story of its potential to revolutionize the field. These assets highlighted the human impact of Ori’s mission, demonstrating how IRO will change lives by bringing curative therapies within reach for millions.

The results speak to the power of Ori’s vision and the strength of the brand we helped create. IRO has already generated significant interest and pre-orders, positioning OriBiotech as a key player in the future of cell and gene therapy manufacturing. More importantly, IRO’s potential to scale production processes promises to unlock the full potential of these therapies, delivering brighter futures to patients worldwide.